Policy & Regulation
FDA approves Genentech's Tecentriq combination therapy for stage III colon cancer
9 October 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Friday that the US Food and Drug Administration (FDA) has approved Tecentriq (...
Sophos IRB and ALCMI partner to support lung cancer research
9 October 2026 - Sophos IRB Inc, an independent, oncology-focused central institutional review board, announced on Thursday a strategic partnership with the Addario Lung Cancer Medical Institute (ALCM...
Innovent Biologics achieves primary study endpoint for inactive thyroid eye disease antibody
9 October 2026 - Chinese biopharmaceutical company Innovent Biologics Inc (HKEX:01801) announced on Thursday that its recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody, SYCUME (...
argenx reports positive Phase 2 results for FB102 in coeliac disease
8 October 2026 - European immunology company argenx SE (EBR & NASDAQ: ARGX) on Thursday reported positive top-line results from a Phase 2 study of FB102, a first-in-class CD122 inhibitor, in adult...
Vir Biotechnology's VIR-5500 receives FDA Fast Track designation for prostate cancer
8 October 2026 - Clinical-stage biopharmaceutical company Vir Biotechnology Inc (Nasdaq:VIR) announced on Thursday that the US Food and Drug Administration (FDA) has granted Fast Track designation to ...
FDA accepts Bayer's application for KERENDIA in chronic kidney disease without diabetes
8 October 2026 - German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY) said on Thursday that the US Food and Drug Administration (FDA) has accepted its supplemental New Drug ...